Incidence, prevalence, and medical expenditures of classical amyotrophic lateral sclerosis in Taiwan, 1999–2008  by Tsai, Ching-Piao et al.
Journal of the Formosan Medical Association (2015) 114, 612e619Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.j fma-onl ine.comORIGINAL ARTICLEIncidence, prevalence, and medical
expenditures of classical amyotrophic lateral
sclerosis in Taiwan, 1999e2008Ching-Piao Tsai a,f, Kai-Chen Wang b, Chi-Shin Hwang c,
I-Ta Lee d, Charles Tzu-Chi Lee e,f,*aNeurology, Neurological Institute, Taipei Veterans General Hospital and National Yang-Ming
University, Taipei, Taiwan
bDepartment of Neurology, Cheng Hsin General Hospital, Taipei, Taiwan
cDepartment of Neurology, Taipei City Hospital, Zhong-Hsiao Branch, Taipei, Taiwan
dDepartment of Physiology and Pharmacology, Chang Gung University, Kwei-San, Tao-Yuan, Taiwan
eDepartment of Public Health, Kaohsiung Medical University, Kaohsiung, TaiwanReceived 20 June 2012; received in revised form 23 January 2013; accepted 24 January 2013KEYWORDS
amyotrophic lateral
sclerosis;
incidence;
medical expenditure;
prevalenceConflicts of interest: The authors
* Corresponding author. Number 100
E-mail address: charles@kmu.edu.
f Dr. Ching-Piao Tsai and Dr. Charles
0929-6646/$ - see front matter Copyr
http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Amyotrophic lateral sclerosis (ALS) is a rare disease, which makes the
estimation of incidence and prevalence difficult in Taiwan. This study was conducted to inves-
tigate the incidence, prevalence, and medical expenditure of ALS in Taiwan.
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Amyotrophic lateral sclerosis in Taiwan 613Conclusion: The incidence and average medical expenditure of ALS patients remained stable
over the years in Taiwan, however, as a proportion of total medical expenses, expenditure
on ventilator and riluzole decreased over the study period.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disease; without mechanical ventilation, death
resulting from respiratory failure usually occurs within 2e5
years from the onset of symptoms.1 Mechanical ventilation
is an effective means of relieving the symptoms of chronic
hypoventilation and prolonging life in patients with ALS.2
The only drug used for treatment, riluzole, can improve
the quality of life and survival of ALS patients.3
ALS is a rare disease, which makes the estimation of
incidence and prevalence difficult. Upon reviewing previous
studies, only one study attempted to report the incidence
and prevalence of motor neuron disease using the National
Health Insurance Database4 in Taiwan. As a result, the
current documentation on classical ALS incidence in Taiwan
was limited. Although increases in prevalence and inci-
dence of ALS have been observed in Hong Kong,5 Japan,6
Sweden7 and, possibly, worldwide, little was known about
the trend of prevalence and incidence in Taiwan. In addi-
tion, the medical expenditure on ALS in Taiwan remained to
be clarified as well. The aim of this study was then to
investigate the incidence, prevalence and medical expen-
diture of ALS in Taiwan from a population-based database.Materials and methods
National health insurance in Taiwan
In 1995, National Health Insurance (NHI), a government-run
insurer with a single-payer insurance system, was estab-
lished in Taiwan with the goal of ensuring health coverage
for the entire population, and to avoid social problems
caused by poverty and disease. The characteristics of NHI
include: payroll-related premiums shared between em-
ployers, employees and the government; fees-for services
under the global budget; and the requirement of co-
payment for medication, ambulatory and inpatient care.
As enrollment onto NHI was mandatory, by December
2008, there were 22.918 million individuals enrolled in the
program nationwide, with a coverage rate of 99.5%. The
increase in coverage is evident when this is compared with
the 92% enrollments at the launching in 1995. The Bureau of
NHI (BNHI) contracted almost 93.3% of medical institutions
nationwide, providing the public with comprehensive
medical benefit coverage, such as hospitalization, day care
for those with mental illness and social rehabilitation. The
registration of all serious disabilities database (SDD) dis-
eases, such as chronic renal failure, myasthenia gravis,
cancer, and ALS, was required by the BNHI before certifi-
cation for SDD could be granted. A group of neurology
specialists at BNHI reviewed the medical records of ALSpatients under El Escorial criteria.8 There were 37,099
registered medical doctors with 553 neurology specialists in
Taiwan in 2008. Furthermore, there were 790,621 in-
dividuals with SDD certificates in 2008, which constituted
3.4% of the total population.
Sample
This was a retrospective population-based study. The
research data was obtained from the National Health In-
surance Research Database (NHIRD), provided by the Na-
tional Health Research Institute, which included
outpatient, ambulatory, hospital inpatient care, as well as
dental services. In addition, the ALS cases were identified
in accordance with the International Classification of Dis-
ease, Ninth revision (ICD-9), codes of 335.20.
ALS is a heterogeneous disease, including, ICD-9 335.00
(anterior horn cell disease), 335.21 (progressive muscular
atrophy involving lower motor neurons), 335.24 (primary
lateral sclerosis involving upper motor neurons), 335.29
(other motor neuron disease), 335.8 (other anterior horn
cell disease), and 335.9 (anterior horn cell disease unspec-
ified), therefore, the prognosis and medical expenditures
had large variations for different types of ALS. For statistical
analysis, we only recruited the patients defined by 335.20,
which represents classical ALS, involving upper and lower
motor neurons. We did this to reach a more homogeneous
result. Any medical claims made by ALS patients between
2004 and 2007 from NHIRD in Taiwan were collected for
analysis. The approval of SDD certificates required strict
evaluation by the BNHI, because patients with SDD certifi-
cates were eligible for exemption from insurance premiums
and co-payments. In this study, the ALS subjects with SDD
certificates between 1999 through 2008 were also included
for the calculation of incidence and prevalence.
Generally, ALS is uncommon in young adults and even
more unusual in children. The ALS onset age was 14e89 in a
UK study9 and 18e94 in an Italian study.10 In this study,
there were 13 cases holding ALS SDD certificates with a
diagnosis at less than 15 years of age (range 0.1e14.8
years). The diagnosis of these 13 children may be unreli-
able. We excluded these 13 cases from the analysis.
Therefore, for the main study database, SDD, we included
1136 ALS cases aged 15.8e89.0, from the years 1999e2008.
For comparison purposes, we also excluded patients with a
first diagnosis age at less than 15 years in the calculation of
incidence and prevalence using NHIRD.
The estimation of incidence and prevalence among
ALS patients
In this study, patients with a primary diagnosis of ALS,
aged more than 15 years, who had made their first service
614 C.-P. Tsai et al.claim either as an outpatient or inpatient were identified
as a “suspected case”. After their first ALS service claim,
patients who had made another medical claim and the
duration was more than x months after their ALS diagnosis
were identified as “x-month-confirmed cases”. The inci-
dence of this type of case was calculated and tracked
back to the date of first diagnosis. In our study, we
calculated data for 1-, 2-, 3-, and 6-month-confirmed
cases. The incidence and prevalence of individuals with
SDD certificates, aged more than 15 years, was compared
with the “6-month-confirmed cases” data compiled from
the NHIRD. The incidence and prevalence of SDD certifi-
cates was also calculated and tracked back to their first
ALS medical claim date. The population in the study
period increased slowly from 22.09 million in 1999 to
23.04 million in 2008. The annual incidence was calcu-
lated as a rate of new cases divided by the yearly overall
population in Taiwan. The calculation of prevalence was
performed in a similar way with the exception of currently
observed cases. The age-standardized incidence and
prevalence were calculated by the year 2000 world stan-
dard population. Calculations were carried out using SAS
9.2.
The survival curve of ALS
All ALS patients were verified by linking the encrypted
identification numbers with the SDD certificates. All ALS
study patients had SDD certificates and were followed
until December 31, 2008 on the national mortality data-
base in order to understand the survival curve of ALS in
Taiwan.Table 1 Diagnoses of ALS in Taiwan, 2005e2006.
Data Year New cases Incidencea
T M F T M F
D1 2004 d d d d d d
2005 437 282 155 1.92 2.44 1.38
2006 346 209 137 1.51 1.80 1.21
2007 338 205 133 1.47 1.77 1.17
D2 2004 d d d d d d
2005 216 135 81 0.94 1.16 0.72
2006 193 111 82 0.84 0.96 0.72
D3 2004 d d d d d d
2005 187 115 72 0.82 0.99 0.64
2006 171 95 76 0.74 0.82 0.67
D4 2004 d d d d d d
2005 174 106 68 0.76 0.91 0.60
2006 161 88 73 0.70 0.76 0.64
D5 2004 d d d d d d
2005 154 97 57 0.67 0.84 0.51
2006 136 76 60 0.59 0.65 0.53
Diagnoses of ALS were recorded in the National Health Insurance Res
335.20. D2: At least two medical claims and more than 1 month after
more than 2 months after first diagnosis of ICD: 335.20. D4: At least tw
ICD: 335.20. D5: At least two medical claims and more than 6 month
ALS Z amyotrophic lateral sclerosis; T Z total; M Z male; F Z fem
a Per 100,000.Results
The incidence and prevalence of ALS in Taiwan
The sex-specific annual incidence and prevalence from the
NHIRD, including outpatient and hospitalization data of
ALS, are presented in Table 1. There were 783 “new sus-
pected cases” with a first diagnosis between 2005 and
2006. These included 491 males and 292 females, and the
average male-to-female ratio was 1.68. However, 6
months after first ALS diagnosis, there were only 290 out of
the 783 suspected cases, which included 173 males and
117 females with an average male-to-female ratio of 1.49.
There were 493 (63.0%) false positives, including 318 males
and 175 females and a male-to-female ratio 1.82. As for
ALS patients, there were 236 new SDD certificates regis-
tered during 2005 and 2006, these included 154 males and
82 females with a male-to-female ratio of 1.90 (Table 2).
The average annual incidence of 6-month-confirmed new
cases during 2005 and 2006 calculated from NHIRD was
0.63 (per 105). This was substantially different in the
population-based calculation, the average annual inci-
dence during 2005 and 2006 for the SDD cases was 0.52
(per 105).
There were a total of 2521 “suspected cases” with an
ALS diagnosis during 2004e2006, including 1541 males and
976 females with a male-to-female ratio of 1.59. Six months
after diagnosis, there were only 1654 confirmed cases from
the 2915 suspected cases. These included 985 males and
669 females with a male-to-female ratio of 1.47. For ALS
patients, there were 1184 SDD certificates either being held
or newly registered during 2004e2006, which included 689Total cases Prevalencea
M/F T M F T M F M/F
d 858 527 329 3.78 4.57 2.95 1.60
1.82 868 539 329 3.81 4.66 2.94 1.64
1.53 805 487 318 3.52 4.20 2.82 1.53
1.54 828 489 339 3.61 4.21 2.99 1.44
d 646 391 255 2.84 3.38 2.28 1.53
1.67 649 387 262 2.84 3.34 2.32 1.48
1.35 627 373 254 2.73 3.21 2.24 1.47
d 616 371 245 2.71 3.21 2.19 1.51
1.60 620 366 254 2.71 3.16 2.25 1.44
1.25 594 350 244 2.59 3.01 2.15 1.43
d 600 360 240 2.64 3.11 2.14 1.50
1.56 606 356 250 2.65 3.07 2.22 1.42
1.21 570 332 238 2.48 2.86 2.10 1.39
d 568 346 222 2.49 2.99 1.98 1.56
1.70 574 342 232 2.51 2.95 2.06 1.47
1.27 512 297 215 2.23 2.56 1.89 1.38
earch Database and made according to ICD:335.20. D1: Any ICD:
first diagnosis of ICD: 335.20. D3: At least two medical claims and
o medical claims and more than 3 months after first diagnosis of
s after first diagnosis of ICD: 335.20.
ale; M/F Z male-to-female ratio.
Table 2 Incidence and prevalence of ALS in Taiwan, 1999e2008.
Year New cases Incidencea Total cases Prevalencea
T M F T1 T2 M F M/F T M F T1 T2 M F M/F
1999 119 74 45 0.54 0.55 0.65 0.42 1.64 181 109 72 0.82 0.83 0.96 0.67 1.51
2000 102 67 35 0.46 0.46 0.59 0.32 1.91 208 131 77 0.93 0.93 1.15 0.71 1.70
2001 100 56 44 0.45 0.44 0.49 0.40 1.27 231 132 99 1.03 1.01 1.15 0.90 1.33
2002 116 76 40 0.52 0.50 0.66 0.36 1.90 280 167 113 1.24 1.19 1.45 1.02 1.48
2003 114 78 36 0.50 0.48 0.68 0.32 2.17 329 193 136 1.46 1.37 1.68 1.23 1.42
2004 122 71 51 0.54 0.50 0.62 0.46 1.39 362 202 160 1.60 1.46 1.75 1.44 1.26
2005 115 71 44 0.51 0.46 0.61 0.39 1.61 393 229 164 1.73 1.55 1.98 1.46 1.40
2006 121 83 38 0.53 0.46 0.72 0.34 2.18 429 258 171 1.88 1.65 2.23 1.52 1.51
2007 104 60 44 0.45 0.39 0.52 0.39 1.36 452 266 186 1.97 1.67 2.29 1.64 1.43
2008 123 73 50 0.53 0.46 0.63 0.44 1.46 478 277 201 2.07 1.72 2.38 1.76 1.38
The incidence and prevalence of ICD:335.20 ALS as taken from the serious disability database. T1: Crude rate. T2: Age-standardized
rate, 2000 population in Taiwan as standard population.
ALS Z amyotrophic lateral sclerosis; T Z total; M Z male; F Z female; M/F Z male-to-female ratio.
a Per 100,000.
Amyotrophic lateral sclerosis in Taiwan 615males and 495 females with a male-to-female ratio of 1.39
(Table 2). The average annual prevalence of ALS cases as
calculated from the NHIRD during 2004e2006 with the “6-
month-confirmed cases” criteria was 2.41 (per 105). The
average annual prevalence during 2004e2006 for the SDD
cases was substantially different at 1.74 (per 105). The
difference in incidence and prevalence between NHIRD and
SDD is mostly caused by false positives in the calculation
when using NHIRD. Therefore, we used SDD data instead of
NHIRD for further calculation. Between the years 2006
through 2008, the average annual incidence and prevalence
of ALS calculated from the SDD database was 0.51 and 1.97
(per 105) in Taiwan, respectively.The diagnosis age of ALS in Taiwan
The diagnosis age (mean  SD) of the new ALS cases was
56.6  13.2 on average and it remained stable during the
years 1999 to 2008. The diagnosis age for males was
57.1  13.3, which was similar to that of females at
55.9  13.1 during 1999e2008 (Table 3).Table 3 Diagnosis age of ALS in Taiwan, 1999e2008.
Year New cases
No. Mean age SD Min Max No. Mean a
1999 119 56.4 12.0 26.7 82.3 74 57.6
2000 102 55.0 13.6 18.2 81.5 67 53.3
2001 100 56.2 12.9 16.8 83.2 56 56.6
2002 116 55.8 15.3 15.8 82.6 76 55.7
2003 114 56.2 12.1 25.6 80.2 78 57.3
2004 122 56.8 14.4 16.7 85.4 71 57.2
2005 115 57.2 13.1 17.5 83.1 71 59.4
2006 121 59.5 12.5 26.2 86.6 83 60.6
2007 104 57.8 12.2 23.9 84.3 60 58.4
2008 123 55.4 13.4 17.1 89.0 73 54.1
1999e2008 1136 56.6 13.2 15.8 89.0 709 57.1
Diagnoses of ICD:335.20 ALS as taken from the serious disability databaWith regards to the distribution of diagnosis age for ALS,
it was found in the study that the diagnosis age apparent
occurred in the age group of 60e69 years for both males
and females (Table 4).The medical expenditure of ALS in Taiwan
It was found in the study, in spite of the increased number
of patients undergoing invasive ventilator care with time,
the proportion of ventilator usage remained steady (ranging
from 16.5% to 20.5%). Furthermore, the annual average
expenditure from invasive ventilator varied during the
study period. Since riluzole was being paid for by the NHI
for ALS patients from 1999, this drug prevalence use had
increased from 77 in 1999 to 266 in 2008. As a result, around
56% of patients were treated by riluzole in 2007e2008,
while the annual average expenditure per patient using
riluzole remained stable and at 88,000 (NTD) in 2008
(Table 5). In this study, there were 694 riluzole users with
mean length of time as 18.28 months (SDZ 23.17 months),
1999e2008. The proportion of total medical expensesMale Female
ge SD Min Max No. Mean age SD Min Max
11.1 26.8 77.5 45 54.4 13.2 26.7 82.3
13.3 24.7 81.5 35 58.3 13.8 18.2 78.3
13.3 16.8 83.2 44 55.7 12.4 22.0 80.1
15.1 18.4 81.4 40 56.0 16.0 15.8 82.6
12.3 25.6 80.2 36 53.7 11.3 29.6 78.0
16.0 16.7 85.4 51 56.1 12.1 31.3 82.7
11.4 33.0 83.1 44 53.5 14.9 17.5 75.2
12.8 28.6 86.6 38 57.1 11.8 26.2 79.3
11.5 36.3 80.6 44 57.1 13.1 23.9 84.3
13.9 17.1 80.0 50 57.2 12.5 32.7 89.0
13.3 16.7 86.6 427 55.9 13.1 15.8 89.0
se. ALSZ amyotrophic lateral sclerosis; SDZ standard deviation.
Table 4 Age distribution of ALS in Taiwan, 1999e2008.
Age group New cases Incidencea Total cases Prevalencea
T M F T M F M/F T M F T M F M/F
15e19 9 5 4 0.01 0.02 0.01 1.25 14 7 7 0.02 0.02 0.02 1.00
20e29 22 15 7 0.06 0.08 0.04 2.14 42 27 15 0.11 0.14 0.08 1.80
30e39 91 56 35 0.24 0.30 0.19 1.60 214 132 82 0.57 0.70 0.44 1.61
40e49 235 133 102 0.65 0.72 0.57 1.30 806 430 376 2.21 2.34 2.08 1.14
50e59 281 175 106 1.15 1.44 0.86 1.65 913 526 387 3.73 4.32 3.15 1.36
60e69 312 204 108 2.10 2.82 1.41 1.89 844 515 329 5.67 7.12 4.30 1.57
70 186 121 65 1.30 1.64 0.94 1.86 510 327 183 3.57 4.43 2.65 1.79
Information on ICD:335.20 ALS was taken from the serious disability database.
ALS Z amyotrophic lateral sclerosis; T Z total; M Z male; F Z female; M/F Z male-to-female ratio.
a Per 100,000.
616 C.-P. Tsai et al.contributed to by ventilator and riluzole expenditure
decreased from 55% of the total in 2000 to 33% in 2008
(Fig. 1).The average medical expenditure per ALS patient
was 353,000 (NTD), representing 16-fold of the general
population of Taiwan in 2008 (Table 6).Table 5 Medical expenditure on ALS in Taiwan, 1999e2008.
Drug (treatments) Year
No.
Invasive ventilator 1999 32
2000 40
2001 38
2002 56
2003 64
2004 73
2005 74
2006 88
2007 87
2008 97
Non-invasive ventilator 1999 6
2000 13
2001 19
2002 13
2003 18
2004 20
2005 18
2006 32
2007 31
2008 38
Riluzole 1999 77
2000 95
2001 116
2002 113
2003 145
2004 183
2005 155
2006 212
2007 253
2008 266
This information about cases of ICD:335.20 ALS was taken from the sDiscussion
This study contained the largest sample size and the longest
study period investigating the incidence and prevalence of
ALS in Taiwan. In order to limit time delay, the incidencePatients Average expenditure
per patient (1000 NTD)Proportion of prevalence
cases (%)
17.7 379
19.2 363
16.5 611
20.0 600
19.5 474
20.2 642
18.8 410
20.5 498
19.2 412
20.3 288
3.3 10
6.3 13
8.2 20
4.6 11
5.5 7
5.5 11
4.6 11
7.5 9
6.9 18
7.9 49
42.5 65
45.7 96
50.2 97
40.4 98
44.1 80
50.6 83
39.4 97
49.4 100
56.0 95
55.6 88
erious disability database. ALS Z amyotrophic lateral sclerosis.
Figure 1 Proportion of average medical expenditure per ALS
patient by ventilator, riluzole and other services in Taiwan,
2000e2008.
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Amyotrophic lateral sclerosis in Taiwan 617and prevalence of SDD certificates were tracked back to
patients’ first ALS medical claim date. It was found in the
study that the 6-month-confirmed incidence was 0.59 (per
105) from NHIRD in 2006, while the incidence was 0.53 (per
105) in the same year from SDD (Tables 1 and 2). It was
concluded from our population-based data that the true
incidence of ALS in Taiwan was between 0.53 and 0.59 (per
105), which was much smaller than that of the Western
countries (Table 7).4,5,11,13e20
However, it was also discovered that the male-to-female
ratio in ALS incidence in Taiwan varied every year, with the
annual average of 1.69 between 1999 and 2008. Due to the
high quality and stability of SDD data, it provided us with
confidence in estimating the incidence of ALS in Taiwan.
According to the data, the incidence of ALS remained stable
between the years 1999 and 2008. Throughout the study
period (1999e2008), the population’s age structure was
stable in Taiwan and the age-standardized incidence was
similar to the crude incidence of ALS. This stable temporal
trend of ALS incidence was consistent with findings in
southern Europe.11
However, the prevalence calculated from SDD showed
an obvious upward temporal trend from 0.82 (per 105) in
1999 to 2.07 (per 105) in 2008. As the Kaplan-Meier survival
curves showed that the survival rate of ALS patients was
similar after year 2003 (Fig. 2), the increased age-
standardized prevalence trend cannot be explained by
the improvement of the survival rate. Furthermore, it
should be noted that the survey time effect on the esti-
mation of prevalence by SDD might lead to bias in the
data. That is, the early study periods had missed cases,
and new cases accumulated with time. Consequently, the
missed cases would become diluted and less significant. As
a result, the observed increasing trend of prevalence from
the SDD data might be confused by the survey time effect.
The observed prevalence of 2.07 (per 105) in 2008 was
close to the 1.97 (per 105) in 2007. The bias from the
survey time effect was therefore mild in 2008. The NHIRD
in certain months confirmed that prevalence that was
calculated based on yearly medical claims could reduce
the survey time effect. The NHIRD 6-month-confirmed
Table 7 Epidemiology studies of ALS in the world.
Area Country Study period Incidence (per 105)
Crude rate Sex ratio
(male/female)
Asia Taiwana,4 2000e2005 1.05 1.51
Taiwanb (present study) 1999e2000 0.50 1.77
Taiwanb (present study) 2001e2005 0.50 1.67
Taiwanb (present study) 2006e2008 0.50 1.67
Hong Kong5 1997e2002 0.60 1.72
Japan13 1995e2004 1.07
Europe Southern Europe11 1964e2009 1.82
Europe14 1998e1999 2.16 1.25
France15 1997e2007 2.50
Norway16 1988e2007 2.17
Southern Italy17 1998e1999 1.60 1.60
Canada18 2000e2004 2.40
Middle East Isfahan, Iran 2002e2006 0.42
North American Western Washington state, USA19 1990e1995 2.1
South American Uruguay20 2002e2003 1.37 2.0
Pacific Ocean Guam21 1950e1989 7.0
a Included, ICD-9: 335 (anterior horn cell disease), 335.20 (amyotrophic lateral sclerosis), 335.21 (progressive muscular atrophy),
335.22 (progressive bulbar palsy), 335.24 (primary lateral sclerosis), 335.29 (other motor neuron disease), 335.8 (other anterior horn cell
disease) and 335.9 (anterior horn cell disease, unspecified).
b Included, ICD-9: 335.20 (amyotrophic lateral sclerosis).
618 C.-P. Tsai et al.cases prevalence was 2.23 (per 105) in 2006, which was
close to the SDD prevalence at 1.88. It is likely that the
prevalence calculated based on these two databases will be
even closer in future years due to the reduced time effect
on SDD, as well as more accurate diagnosis of ALS in NHIRD
data.
Due to the fact that the diagnosis age of the disease was
calculated tracking back to each patient’s first diagnosis
date, the time delay was thereby limited in this study. The
average diagnosis age was 56.6 years old, and peaked at the
60e69 age group for both males and females. Between the
years 2005 and 2007, it was found that despite the de-
creases in the new suspected cases and confirmed cases at
various months, the new SDD certificates remained stable.Figure 2 Kaplan-Meier survival curves from diagnosis for
amyotrophic lateral sclerosis cases by diagnosis period in
Taiwan, 1999e2008, n Z 1136. Log-rank test, p Z 0.022.It was also demonstrated in this study that in 2005 and
2006, as many as 52% of suspected cases were excluded
within 1 month after first diagnosis. This in turn, repre-
sented improvements in the accuracy of ALS diagnosis with
time. However, the fact that the number of confirmed
cases had decreased steadily from 1 month to 6 months
after the first diagnosis date showed that accurate diag-
nosis was still difficult in the early phase of ALS in Taiwan.
In addition, it was evident from the study that the
number of people treated with a ventilator and riluzole
remained stable with time. The average medical expendi-
ture per ALS patient was 16-fold greater than the general
population of Taiwan in 2008. When compared with other
SDD, the average medical expenditure was 120-fold greater
than hematophili, 31-fold ventilator-dependent patients,
26-fold dialysis and 6-fold cancer.12 The proportion of
average medical expenditures per ALS patient from venti-
lator and riluzole compared with other medical services
decreased with time, which implies the health care was
improving for ALS patients in Taiwan.Financial disclosure
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